Embedded Files
MS/PhD combined candidate (2017, 03 - 2023, 02)
2018 GPF (Global Ph.D Fellowship)
Post-Doc (2023, 02 -2023, 10)
Current: Post-Doc in St. Jude Children's Hospital, TN, USA
12. Eom, S., Park, S. G., Jun, H., Kim, Y., Lee, H. B., and Kang, S.,* Effective in vivo delivery of diphtheria toxin using protein cage nanoparticles for targeted cancer therapy. Acta Biomater, 2025, 202, 517-528.
11. Lee, H. B., Park, S. G., Kim, H. J., Jeon, J. P., Oh, S., Lee, S., Park, S. H., and Kang, S.,* CD7-Targeted Cytotoxic Potency of Diphtheria Toxin- and Ricin-based Immunotoxins in Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia. Mol. Pharm., 2025, 22, 3255-3267.
10. Eom, S.,# Park, S. G.,# Koo, Y. H.,# Noh, Y., Choi, C., Kim, Y., Jun, H., Cha, C., Joo, J., and Kang, S.* In Situ Forming and Self-crosslinkable Protein Hydrogels for Localized Cancer Therapy and Topical Wound Healing. J. Control. Release, 2025, 378, 460-475.
# Equal contribution
9. Park, S. G., Lee, H. B., and Kang, S.* Development of plug-and-deliverable intracellular protein delivery platforms based on botulinum neurotoxin. Int. J. Biol. Macromol., 2024, 261, 129622.
8. Park, S. G.,# Kim, H. J.,# Lee, H. B., Eom, S., Jun, H., Jang, Y., Park, S. H.* and Kang, S.* Protein cage nanoparticle-based NK cell-engaging nanodrones (NKeNDs) effectively recruit NK cells to target tumor sites and suppress tumor growth. Nano Today, 2024, 54, 102075.
7. Kang, Y., Yeo, M., Choi, H., Jun, H., Eom, S., Park, S. G., Yoon, H., Kim, E.,* and Kang, S.* Lactate Oxidase/vSIRPa Conjugates Efficiently Consume Tumor-produced Lactate and Locally Produce Tumor-necrotic H2O2 to Suppress Tumor Growth. Int. J. Biol. Macromol., 2023, 231, 123577.
6. Choi, H., Yeo, M., Kang, Y., Kim, H. J., Park, S. G., Jang, E., Park, S. H.,* Kim, E.,* and Kang, S.* Lactate Oxidase/Catalase-displaying Nanoparticles Efficiently Consume Lactate in the Tumor Microenvironment to Effectively Suppress Tumor Growth. J. Nanobiotechnology, 2023, 21, 5.
5. Park, S. G., Kim, H., Jun, H., Choi, S. Y., Kim, E.,* and Kang, S.* Directing Ricin-based Immunotoxins with Targeting Affibodies and KDEL Signal Peptide to Cancer Cells Effectively Induces Apoptosis and Tumor Suppression. J. Nanobiotechnology, 2022, 20, 387.
4. Jun, H., Jang, E., Kim, H., Yeo, M., Park, S. G., Lee, J., Shin, K. J., Chae, Y. C. Kang, S.,* and Kim, E.* TRAIL & EGFR Affibody Dual-display on a Protein Cage Nanoparticle Synergistically Suppresses Tumor Growth. J. Control. Release, 2022, 349, 367-378.
3. Kim, H., Jin, S., Choi, H., Kang, M., Park, S. G., Jun, H., Cho, H., and Kang, S.,* Target-Switchable Gd(III)-DOTA/Protein Cage Nanoparticle Conjugates with Multiple Targeting Affibody Molecules as Target Selective T1 Contrast Agents for High-field MRI. J. Control. Release, 2021, 335, 269-280.
2. Park, S. G., Choi, B., Bae, Y., Lee, Y. G., Park, S. A., Chae, Y. C., and Kang, S.,* Selective and Effective Cancer Treatments using Target-Switchable Intracellular Bacterial Toxin Delivery Systems. Adv. Therap., 2020, 3, 202000043.
1. Bae, Y., Kim, G.J., Kim, H., Park, S.G., Jung, H.S., and Kang, S.* Engineering Tunable Dual Functional Protein Cage Nanoparticles using Bacterial Superglue. Biomacromolecules, 2018, 19, 2896-2904.
Page updated
Google Sites
Report abuse